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A candidate tetravalent dengue vaccine is being assessed in
three clinical trials involvingmore than 35,000 children between
the ages of 2 and 16 years in the Asia-Pacific and Latin Ameri-
can countries. We report the results of long-term follow-up
interim analyses and integrated efficacy analyses.
We are assessing the incidence of hospitalization for viro-
logically confirmed dengues a surrogate safety end point during
follow-up in years 3–6 of two phase 3 trials, CYD14 and CYD15,
and a phase 2b trial, CYD23/57. We estimated vaccine effi-
cacy using pooled data from the first 25 months of CYD14 and
CYD15.
Follow-up data were available for 10,165 of 10,275 partici-
pants (99%) in CYD14 and19,898 of 20,869 participants (95%)
in CYD15. Data were available for 3203 of the 4002 partici-
pants (80%) in the CYD23 trial included in CYD57. During year
3 in the CYD14, CYD15, and CYD57 trials combined, hospital-
ization for virologically confirmed dengue occurred in 65 of
22,177 participants in the vaccine group and 39 of 11,089
participants in the control group. Pooled relative risks of hos-
pitalization for dengue were 0.84 (95% confidence interval [CI],
0.56–1.24) among all participants, 1.58 (95% CI, 0.83–3.02) among
those under the age of 9 years, and 0.50 (95% CI, 0.29–0.86)
among those 9 years of age or older. During year 3, hospital-
ization for severe dengue, as defined by the independent data
monitoring committee criteria, occurred in 18 of 22,177 par-
ticipants in the vaccine group and 6 of 11,089 participants in
the control group. Pooled rates of efficacy for symptomatic
dengue during the first 25 months were 60.3% (95% CI, 55.7–
64.5) for all participants, 65.6% (95% CI, 60.7–69.9) for those 9
years of age or older, and 44.6% (95% CI, 31.6–55.0) for those
younger than 9 years of age.
Although the unexplained higher incidence of hospitaliza-
tion for dengue in year 3 among children younger than 9 years
of age needs to be carefully monitored during long-term follow-
up, the risk among children 2–16 years of age was lower in the
vaccine group than in the control group.
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